ID   NANOG_MOUSE             Reviewed;         305 AA.
AC   Q80Z64; Q6SMR1; Q7TN85;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   07-APR-2021, entry version 151.
DE   RecName: Full=Homeobox protein NANOG;
DE   AltName: Full=ES cell-associated protein 4;
DE   AltName: Full=Early embryo specific expression NK-type homeobox protein;
DE   AltName: Full=Homeobox transcription factor Nanog;
GN   Name=Nanog; Synonyms=Ecat4, Enk;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, DNA-BINDING,
RP   DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=12787504; DOI=10.1016/s0092-8674(03)00393-3;
RA   Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K.,
RA   Maruyama M., Maeda M., Yamanaka S.;
RT   "The homeoprotein Nanog is required for maintenance of pluripotency in
RT   mouse epiblast and ES cells.";
RL   Cell 113:631-642(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, DEVELOPMENTAL STAGE, AND
RP   TISSUE SPECIFICITY.
RC   STRAIN=129/Ola; TISSUE=Embryonic stem cell;
RX   PubMed=12787505; DOI=10.1016/s0092-8674(03)00392-1;
RA   Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S.,
RA   Smith A.;
RT   "Functional expression cloning of Nanog, a pluripotency sustaining factor
RT   in embryonic stem cells.";
RL   Cell 113:643-655(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND DEVELOPMENTAL STAGE.
RC   STRAIN=FVB/NJ; TISSUE=Embryonic stem cell;
RX   PubMed=12609610; DOI=10.1016/s1567-133x(03)00005-x;
RA   Wang S.-H., Tsai M.-S., Chiang M.-F., Li H.;
RT   "A novel NK-type homeobox gene, ENK (early embryo specific NK),
RT   preferentially expressed in embryonic stem cells.";
RL   Gene Expr. Patterns 3:99-103(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), DEVELOPMENTAL STAGE, AND
RP   TISSUE SPECIFICITY.
RC   STRAIN=C57BL/6J;
RX   PubMed=15108323; DOI=10.1002/dvdy.20034;
RA   Hart A.H., Hartley L., Ibrahim M., Robb L.;
RT   "Identification, cloning and expression analysis of the pluripotency
RT   promoting Nanog genes in mouse and human.";
RL   Dev. Dyn. 230:187-198(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Embryonic stem cell;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   FUNCTION.
RX   PubMed=14728807; DOI=10.1038/sj.cr.7290193;
RA   Pan G.J., Pei D.Q.;
RT   "Identification of two distinct transactivation domains in the pluripotency
RT   sustaining factor nanog.";
RL   Cell Res. 13:499-502(2003).
RN   [7]
RP   DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=15939376; DOI=10.1016/j.modgep.2005.03.001;
RA   Yamaguchi S., Kimura H., Tada M., Nakatsuji N., Tada T.;
RT   "Nanog expression in mouse germ cell development.";
RL   Gene Expr. Patterns 5:639-646(2005).
RN   [8]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=15502159; DOI=10.1074/jbc.m407847200;
RA   Pan G., Pei D.;
RT   "The stem cell pluripotency factor NANOG activates transcription with two
RT   unusually potent subdomains at its C terminus.";
RL   J. Biol. Chem. 280:1401-1407(2005).
RN   [9]
RP   SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=15582778; DOI=10.1016/j.mod.2004.08.008;
RA   Hatano S.Y., Tada M., Kimura H., Yamaguchi S., Kono T., Nakano T.,
RA   Suemori H., Nakatsuji N., Tada T.;
RT   "Pluripotential competence of cells associated with Nanog activity.";
RL   Mech. Dev. 122:67-79(2005).
RN   [10]
RP   INDUCTION.
RX   PubMed=15619621; DOI=10.1038/ncb1211;
RA   Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., Xu Y.;
RT   "p53 induces differentiation of mouse embryonic stem cells by suppressing
RT   Nanog expression.";
RL   Nat. Cell Biol. 7:165-171(2005).
RN   [11]
RP   INDUCTION.
RX   PubMed=16790525; DOI=10.1096/fj.05-5543fje;
RA   Pan G., Li J., Zhou Y., Zheng H., Pei D.;
RT   "A negative feedback loop of transcription factors that controls stem cell
RT   pluripotency and self-renewal.";
RL   FASEB J. 20:1730-1732(2006).
RN   [12]
RP   INTERACTION WITH SALL4, AND DNA-BINDING.
RX   PubMed=16840789; DOI=10.1074/jbc.c600122200;
RA   Wu Q., Chen X., Zhang J., Loh Y.-H., Low T.-Y., Zhang W., Zhang W.,
RA   Sze S.-K., Lim B., Ng H.-H.;
RT   "Sall4 interacts with Nanog and co-occupies Nanog genomic sites in
RT   embryonic stem cells.";
RL   J. Biol. Chem. 281:24090-24094(2006).
RN   [13]
RP   FUNCTION.
RX   PubMed=16791199; DOI=10.1038/nature04914;
RA   Silva J., Chambers I., Pollard S., Smith A.;
RT   "Nanog promotes transfer of pluripotency after cell fusion.";
RL   Nature 441:997-1001(2006).
RN   [14]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=16518401; DOI=10.1038/ng1760;
RA   Loh Y.-H., Wu Q., Chew J.-L., Vega V.B., Zhang W., Chen X., Bourque G.,
RA   George J., Leong B., Liu J., Wong K.-Y., Sung K.W., Lee C.W., Zhao X.-D.,
RA   Chiu K.-P., Lipovich L., Kuznetsov V.A., Robson P., Stanton L.W.,
RA   Wei C.-L., Ruan Y., Lim B., Ng H.-H.;
RT   "The Oct4 and Nanog transcription network regulates pluripotency in mouse
RT   embryonic stem cells.";
RL   Nat. Genet. 38:431-440(2006).
RN   [15]
RP   FUNCTION, INTERACTION WITH SMAD1, AND INDUCTION.
RX   PubMed=16801560; DOI=10.1073/pnas.0506945103;
RA   Suzuki A., Raya A., Kawakami Y., Morita M., Matsui T., Nakashima K.,
RA   Gage F.H., Rodriguez-Esteban C., Izpisua Belmonte J.C.;
RT   "Nanog binds to Smad1 and blocks bone morphogenetic protein-induced
RT   differentiation of embryonic stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10294-10299(2006).
RN   [16]
RP   INTERACTION WITH ESRRB.
RX   PubMed=18957414; DOI=10.1074/jbc.m803481200;
RA   Zhang X., Zhang J., Wang T., Esteban M.A., Pei D.;
RT   "Esrrb activates Oct4 transcription and sustains self-renewal and
RT   pluripotency in embryonic stem cells.";
RL   J. Biol. Chem. 283:35825-35833(2008).
RN   [17]
RP   INTERACTION WITH NSD2.
RX   PubMed=19483677; DOI=10.1038/nature08086;
RA   Nimura K., Ura K., Shiratori H., Ikawa M., Okabe M., Schwartz R.J.,
RA   Kaneda Y.;
RT   "A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-
RT   Hirschhorn syndrome.";
RL   Nature 460:287-291(2009).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH ZNF281.
RX   PubMed=21915945; DOI=10.1002/stem.736;
RA   Fidalgo M., Shekar P.C., Ang Y.S., Fujiwara Y., Orkin S.H., Wang J.;
RT   "Zfp281 functions as a transcriptional repressor for pluripotency of mouse
RT   embryonic stem cells.";
RL   Stem Cells 29:1705-1716(2011).
RN   [19]
RP   FUNCTION, INTERACTION WITH ZNF281, AND INDUCTION.
RX   PubMed=22988117; DOI=10.1073/pnas.1208533109;
RA   Fidalgo M., Faiola F., Pereira C.F., Ding J., Saunders A., Gingold J.,
RA   Schaniel C., Lemischka I.R., Silva J.C., Wang J.;
RT   "Zfp281 mediates Nanog autorepression through recruitment of the NuRD
RT   complex and inhibits somatic cell reprogramming.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:16202-16207(2012).
RN   [20]
RP   FUNCTION, AND MUTAGENESIS OF THR-101; PHE-103; TYR-120; LEU-123; GLN-125;
RP   MET-126; TYR-137; LYS-138; LYS-141; THR-142; GLN-145; ASN-146; ARG-148;
RP   MET-149 AND LYS-152.
RX   PubMed=25825768; DOI=10.1073/pnas.1502855112;
RA   Hayashi Y., Caboni L., Das D., Yumoto F., Clayton T., Deller M.C.,
RA   Nguyen P., Farr C.L., Chiu H.J., Miller M.D., Elsliger M.A., Deacon A.M.,
RA   Godzik A., Lesley S.A., Tomoda K., Conklin B.R., Wilson I.A., Yamanaka S.,
RA   Fletterick R.J.;
RT   "Structure-based discovery of NANOG variant with enhanced properties to
RT   promote self-renewal and reprogramming of pluripotent stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:4666-4671(2015).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 96-155, INTERACTION WITH DNA,
RP   PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF LYS-112; MET-126; TYR-137;
RP   LYS-138; THR-142; ASN-146 AND GLN-147.
RX   PubMed=18177668; DOI=10.1016/j.jmb.2007.11.091;
RA   Jauch R., Ng C.K.L., Saikatendu K.S., Stevens R.C., Kolatkar P.R.;
RT   "Crystal structure and DNA binding of the homeodomain of the stem cell
RT   transcription factor Nanog.";
RL   J. Mol. Biol. 376:758-770(2008).
CC   -!- FUNCTION: Transcription regulator involved in inner cell mass and
CC       embryonic stem (ES) cells proliferation and self-renewal
CC       (PubMed:25825768). Imposes pluripotency on ES cells and prevents their
CC       differentiation towards extraembryonic endoderm and trophectoderm
CC       lineages. Blocks bone morphogenetic protein-induced mesoderm
CC       differentiation of ES cells by physically interacting with SMAD1 and
CC       interfering with the recruitment of coactivators to the active SMAD
CC       transcriptional complexes. Acts as a transcriptional activator or
CC       repressor. Binds optimally to the DNA consensus sequence 5'-
CC       TAAT[GT][GT]-3' or 5'-[CG][GA][CG]C[GC]ATTAN[GC]-3'. Binds to the
CC       POU5F1/OCT4 promoter (By similarity). Able to autorepress its
CC       expression in differentiating (ES) cells: binds to its own promoter
CC       following interaction with ZNF281/ZFP281, leading to recruitment of the
CC       NuRD complex and subsequent repression of expression. When
CC       overexpressed, promotes cells to enter into S phase and proliferation.
CC       {ECO:0000250|UniProtKB:Q9H9S0, ECO:0000269|PubMed:12787504,
CC       ECO:0000269|PubMed:12787505, ECO:0000269|PubMed:14728807,
CC       ECO:0000269|PubMed:15502159, ECO:0000269|PubMed:16518401,
CC       ECO:0000269|PubMed:16791199, ECO:0000269|PubMed:16801560,
CC       ECO:0000269|PubMed:21915945, ECO:0000269|PubMed:22988117,
CC       ECO:0000269|PubMed:25825768}.
CC   -!- SUBUNIT: Interacts with SMAD1 (PubMed:16801560). Interacts with SALL4
CC       (PubMed:16840789). Interacts with ZNF281/ZFP281 (PubMed:21915945,
CC       PubMed:22988117). Interacts with PCGF1 (By similarity). Interacts with
CC       ESRRB; reciprocally modulates their transcriptional activities
CC       (PubMed:18957414). Interacts with NSD2 (PubMed:19483677).
CC       {ECO:0000250|UniProtKB:Q9H9S0, ECO:0000269|PubMed:16801560,
CC       ECO:0000269|PubMed:16840789, ECO:0000269|PubMed:18957414,
CC       ECO:0000269|PubMed:19483677, ECO:0000269|PubMed:21915945,
CC       ECO:0000269|PubMed:22988117}.
CC   -!- INTERACTION:
CC       Q80Z64; Q61066: Nr0b1; NbExp=7; IntAct=EBI-2312517, EBI-2312665;
CC       Q80Z64; Q9QUR7: Pin1; NbExp=2; IntAct=EBI-2312517, EBI-2432975;
CC       Q80Z64; P20263: Pou5f1; NbExp=4; IntAct=EBI-2312517, EBI-1606219;
CC       Q80Z64; Q6PR54: Rif1; NbExp=5; IntAct=EBI-2312517, EBI-2312621;
CC       Q80Z64; P70414: Slc8a1; NbExp=9; IntAct=EBI-2312517, EBI-2312694;
CC       Q80Z64; P48432: Sox2; NbExp=10; IntAct=EBI-2312517, EBI-2313612;
CC       Q80Z64; Q99LI5: Znf281; NbExp=5; IntAct=EBI-2312517, EBI-2312719;
CC       Q80Z64-1; Q80Z64-1: Nanog; NbExp=2; IntAct=EBI-15699014, EBI-15699014;
CC       Q80Z64-1; P62991: Ubc; NbExp=3; IntAct=EBI-15699014, EBI-413074;
CC       Q80Z64-1; Q13526: PIN1; Xeno; NbExp=2; IntAct=EBI-15699014, EBI-714158;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00108,
CC       ECO:0000269|PubMed:15582778}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q80Z64-1; Sequence=Displayed;
CC       Name=2; Synonyms=Nanog1a, Nanog1b;
CC         IsoId=Q80Z64-2; Sequence=VSP_021689;
CC   -!- TISSUE SPECIFICITY: Not expressed in oocytes and spermatogonia (at
CC       protein level). Not expressed in many somatic organs, ovary, testis,
CC       fibroblast and hematopoietic cell lines. {ECO:0000269|PubMed:12787504,
CC       ECO:0000269|PubMed:12787505, ECO:0000269|PubMed:15108323,
CC       ECO:0000269|PubMed:15939376}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the central portion of the morula,
CC       the inner cell mass (ICM) of the blastocyst, in embryonic stem (ES) and
CC       embryonic germ (EG) cells, in the epiblast between 6.5 and 7.5 dpc, in
CC       primordial germ cells (PGCs) between 7.75 and 12.5 dpc (at protein
CC       level). The expression in PGCs decreases in female germ cells that
CC       entered meiosis at 13.5 dpc and in male germ cells that entered mitotic
CC       arrest at 14.5 dpc (at protein level). Not expressed in unfertilized
CC       eggs or 2- or 8-cell-stage embryos (at protein level). Expressed in the
CC       central portion of the morula, the inner cell mass (ICM) of the
CC       blastocyst, in ES and EG cells, in the epiblast at 6 dpc and in PGCs of
CC       genital ridges between 11.5 and 12.5 dpc. Expression decreases with ES
CC       differentiation. {ECO:0000269|PubMed:12609610,
CC       ECO:0000269|PubMed:12787504, ECO:0000269|PubMed:12787505,
CC       ECO:0000269|PubMed:15108323, ECO:0000269|PubMed:15582778,
CC       ECO:0000269|PubMed:15939376}.
CC   -!- INDUCTION: By the transcription factor POU5F1 in ES cells that acts as
CC       a direct biphasic regulator: a steady-state concentration of POU5F1 up-
CC       regulated its expression, while an elevated concentration of POU5F1
CC       down-regulated its expression. Up-regulated by the transcription factor
CC       FOXD3. Up-regulated in ES cells by transcription factors T (Brachyury)
CC       and STAT3. Down-regulated by p53 in response to DNA damage induced by
CC       ultraviolet light (UV) or doxorubicin. Down-regulated upon ES
CC       differentiation by mediating autorepression through interaction with
CC       ZNF281/ZFP281. {ECO:0000269|PubMed:15619621,
CC       ECO:0000269|PubMed:16518401, ECO:0000269|PubMed:16790525,
CC       ECO:0000269|PubMed:16801560, ECO:0000269|PubMed:22988117}.
CC   -!- DISRUPTION PHENOTYPE: Loss of pluripotency in both ICM and ES cells and
CC       differentiated into extraembryonic (parietal and visceral) endoderm
CC       lineage. {ECO:0000269|PubMed:12787504}.
CC   -!- MISCELLANEOUS: 'Nanog' is derived from 'Tir nan Og' the mythologic
CC       Celtic land of the ever young.
CC   -!- SIMILARITY: Belongs to the Nanog homeobox family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB093574; BAC76998.1; -; mRNA.
DR   EMBL; AY278951; AAP92157.1; -; mRNA.
DR   EMBL; AF507043; AAO67362.1; -; mRNA.
DR   EMBL; AY455282; AAS57554.1; -; mRNA.
DR   EMBL; AY455285; AAS57556.1; -; mRNA.
DR   EMBL; AK010332; BAE43219.1; -; mRNA.
DR   CCDS; CCDS39623.1; -. [Q80Z64-1]
DR   CCDS; CCDS80607.1; -. [Q80Z64-2]
DR   RefSeq; NP_001276757.1; NM_001289828.1.
DR   RefSeq; NP_001276759.1; NM_001289830.1. [Q80Z64-2]
DR   RefSeq; NP_001276760.1; NM_001289831.1. [Q80Z64-2]
DR   RefSeq; NP_082292.1; NM_028016.3. [Q80Z64-1]
DR   RefSeq; XP_006506714.1; XM_006506651.2.
DR   PDB; 2VI6; X-ray; 2.60 A; A/B/C/D/E/F/G/H=96-155.
DR   PDBsum; 2VI6; -.
DR   SMR; Q80Z64; -.
DR   BioGRID; 215050; 288.
DR   DIP; DIP-29932N; -.
DR   ELM; Q80Z64; -.
DR   IntAct; Q80Z64; 154.
DR   MINT; Q80Z64; -.
DR   STRING; 10090.ENSMUSP00000012540; -.
DR   iPTMnet; Q80Z64; -.
DR   PhosphoSitePlus; Q80Z64; -.
DR   PaxDb; Q80Z64; -.
DR   PRIDE; Q80Z64; -.
DR   ProteomicsDB; 287355; -. [Q80Z64-1]
DR   ProteomicsDB; 287356; -. [Q80Z64-2]
DR   Ensembl; ENSMUST00000012540; ENSMUSP00000012540; ENSMUSG00000012396. [Q80Z64-1]
DR   Ensembl; ENSMUST00000112580; ENSMUSP00000108199; ENSMUSG00000012396. [Q80Z64-2]
DR   Ensembl; ENSMUST00000112581; ENSMUSP00000108200; ENSMUSG00000012396. [Q80Z64-2]
DR   GeneID; 71950; -.
DR   KEGG; mmu:71950; -.
DR   UCSC; uc009dpo.2; mouse. [Q80Z64-1]
DR   CTD; 79923; -.
DR   MGI; MGI:1919200; Nanog.
DR   eggNOG; KOG0491; Eukaryota.
DR   GeneTree; ENSGT00670000098076; -.
DR   HOGENOM; CLU_086240_0_0_1; -.
DR   InParanoid; Q80Z64; -.
DR   PhylomeDB; Q80Z64; -.
DR   TreeFam; TF337402; -.
DR   BioGRID-ORCS; 71950; 3 hits in 54 CRISPR screens.
DR   ChiTaRS; Nanog; mouse.
DR   EvolutionaryTrace; Q80Z64; -.
DR   PRO; PR:Q80Z64; -.
DR   Proteomes; UP000000589; Chromosome 6.
DR   RNAct; Q80Z64; protein.
DR   Bgee; ENSMUSG00000012396; Expressed in embryonic stem cell and 46 other tissues.
DR   ExpressionAtlas; Q80Z64; baseline and differential.
DR   Genevisible; Q80Z64; MM.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0005730; C:nucleolus; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001010; F:RNA polymerase II sequence-specific DNA-binding transcription factor recruiting activity; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:MGI.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:MGI.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0043697; P:cell dedifferentiation; IDA:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; IEP:HGNC-UCL.
DR   GO; GO:0001714; P:endodermal cell fate specification; ISO:MGI.
DR   GO; GO:0008406; P:gonad development; IEP:HGNC-UCL.
DR   GO; GO:0001710; P:mesodermal cell fate commitment; IGI:MGI.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0010454; P:negative regulation of cell fate commitment; IDA:MGI.
DR   GO; GO:0042664; P:negative regulation of endodermal cell fate specification; TAS:HGNC-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:MGI.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IDA:MGI.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; ISO:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:MGI.
DR   GO; GO:2000035; P:regulation of stem cell division; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0010033; P:response to organic substance; IDA:MGI.
DR   GO; GO:0032526; P:response to retinoic acid; IDA:MGI.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; ISO:MGI.
DR   GO; GO:0048863; P:stem cell differentiation; IDA:MGI.
DR   GO; GO:0017145; P:stem cell division; IDA:MGI.
DR   GO; GO:0019827; P:stem cell population maintenance; IDA:MGI.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   Pfam; PF00046; Homeodomain; 1.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Developmental protein;
KW   Direct protein sequencing; DNA-binding; Homeobox; Nucleus;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..305
FT                   /note="Homeobox protein NANOG"
FT                   /id="PRO_0000261419"
FT   REPEAT          198..202
FT                   /note="1"
FT   REPEAT          203..207
FT                   /note="2"
FT   REPEAT          208..212
FT                   /note="3"
FT   REPEAT          213..217
FT                   /note="4"
FT   REPEAT          218..222
FT                   /note="5"
FT   REPEAT          223..227
FT                   /note="6"
FT   REPEAT          228..232
FT                   /note="7"
FT   REPEAT          233..237
FT                   /note="8"
FT   REPEAT          238..242
FT                   /note="9"
FT   REPEAT          243..247
FT                   /note="10"
FT   DNA_BIND        96..155
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   REGION          96..155
FT                   /note="Sufficient for interaction with SALL4"
FT                   /evidence="ECO:0000269|PubMed:16840789"
FT   REGION          123..152
FT                   /note="Required for DNA-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H9S0"
FT   REGION          198..247
FT                   /note="10 X repeats starting with a Trp in each unit"
FT   REGION          198..247
FT                   /note="Sufficient for transactivation activity"
FT   REGION          248..305
FT                   /note="Sufficient for strong transactivation activity"
FT   COMPBIAS        198..243
FT                   /note="Trp-rich"
FT   VAR_SEQ         1..25
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15108323"
FT                   /id="VSP_021689"
FT   MUTAGEN         101
FT                   /note="T->A: Decreased protein expression. Decreased
FT                   embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         103
FT                   /note="F->A: Decreased protein expression and stability.
FT                   Decreased embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         112
FT                   /note="K->E: Increases affinity for DNA and protein
FT                   stability; when associated with R-147."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         120
FT                   /note="Y->A: Decreased protein expression and stability.
FT                   Decreased embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         123
FT                   /note="L->A: Increased protein expression and stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         125
FT                   /note="Q->A: Decreased protein expression. No effect on
FT                   protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         126
FT                   /note="M->A: No effect on protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         126
FT                   /note="M->R: Increases affinity for DNA; when associated
FT                   with E-137."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         137
FT                   /note="Y->A: Increased protein expression. Decreased
FT                   protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         137
FT                   /note="Y->E: Increases affinity for DNA; when associated
FT                   with R-126."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         138
FT                   /note="K->A: Decreased protein expression and stability.
FT                   Decreased embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         138
FT                   /note="K->E: Reduced affinity for DNA."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         141
FT                   /note="K->A: Decreased protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         142
FT                   /note="T->A: Decreased protein expression and stability.
FT                   Decreased embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         142
FT                   /note="T->I: Slightly reduced affinity for DNA."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         145
FT                   /note="Q->A: Increased protein expression. No effect on
FT                   protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         146
FT                   /note="N->A: No effect on protein stability. Decreased
FT                   embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         146
FT                   /note="N->E: Strongly reduced affinity for DNA."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         147
FT                   /note="Q->R: Increases affinity for DNA and protein
FT                   stability; when associated with E-112."
FT                   /evidence="ECO:0000269|PubMed:18177668"
FT   MUTAGEN         148
FT                   /note="R->A: Decreased protein stability. Decreased
FT                   embryonic stem cell self-renewal."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         149
FT                   /note="M->A: Increased protein expression. No effect on
FT                   protein stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   MUTAGEN         152
FT                   /note="K->A: Decreased protein expression and stability."
FT                   /evidence="ECO:0000269|PubMed:25825768"
FT   CONFLICT        149
FT                   /note="M -> V (in Ref. 1; BAC76998)"
FT                   /evidence="ECO:0000305"
FT   HELIX           105..117
FT                   /evidence="ECO:0007744|PDB:2VI6"
FT   HELIX           123..133
FT                   /evidence="ECO:0007744|PDB:2VI6"
FT   HELIX           137..149
FT                   /evidence="ECO:0007744|PDB:2VI6"
FT   HELIX           152..154
FT                   /evidence="ECO:0007744|PDB:2VI6"
SQ   SEQUENCE   305 AA;  34240 MW;  4EF96408B767C79F CRC64;
     MSVGLPGPHS LPSSEEASNS GNASSMPAVF HPENYSCLQG SATEMLCTEA ASPRPSSEDL
     PLQGSPDSST SPKQKLSSPE ADKGPEEEEN KVLARKQKMR TVFSQAQLCA LKDRFQKQKY
     LSLQQMQELS SILNLSYKQV KTWFQNQRMK CKRWQKNQWL KTSNGLIQKG SAPVEYPSIH
     CSYPQGYLVN ASGSLSMWGS QTWTNPTWSS QTWTNPTWNN QTWTNPTWSS QAWTAQSWNG
     QPWNAAPLHN FGEDFLQPYV QLQQNFSASD LEVNLEATRE SHAHFSTPQA LELFLNYSVT
     PPGEI
//
